Poolbeg Pharma said partner OneThree Biotech has completed a tailored AI model of its Respiratory Syncytial Virus ('RSV') human challenge data enabling detailed analysis to get underway.
Results of this work are expected in the fourth quarter of 2022.
Poolbeg added it is the first time to its knowledge that AI analysis has been used to identify new drug targets and treatments for RSV using human challenge trial data.
A model will be built to discover and identify the disease signatures that define RSV infection and then identify drugs that can effectively reverse those.
Jeremy Skillington, Poolbeg Pharma’s CEO, said: "OneThree Biotech's AI model optimisation has been completed on time and is on-track to deliver results later this year.
This is the first time that AI has been used to model RSV with the complete longitudinal disease data which can only be produced from human challenge trials.
”We are excited to see the insights into RSV that can be generated from this analysis which will help us to identify the best potential drug candidates to develop.”
-- adds video interview--